RxDoctor Payments Data

Ealon Joelson, MD

Neurology · Palo Alto, CANPI 1770658841

Payments from drug & device makers

$10,980in general payments, 2019–2025

Across 529 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Impel Pharmaceuticals Inc.$662
  • UCB, Inc.$599
  • AstraZeneca$580
  • EMD Serono, Inc.$510
  • plus $5K from 31 others

What the payments were for

  • Speaking & faculty fees$490%
  • Food & beverage$10,49496%
  • Education$4374%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,980 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$569,065
Medicare patients
381
Services billed
62,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a14$134,335
Nurtec OdtRimegepant Sulfate60$78,796
QuliptaAtogepant32$64,575
UbrelvyUbrogepant31$57,554
RytaryCarbidopa/Levodopa17$21,975
Topiramate ErTopiramate30$16,541
XareltoRivaroxaban13$15,534
Aimovig AutoinjectorErenumab-Aooe12$8,764
Memantine Hcl103$6,940
Lacosamide24$6,032
MaxaltRizatriptan Benzoate11$5,194
Gabapentin184$4,564
Pregabalin78$3,093
Topiramate55$2,570
Sumatriptan Succinate57$2,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$213$134,33514 claims
AbbVieQulipta, Ubrelvy$2,908$122,13063 claims
PfizerNurtec Odt$485$78,79660 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$106$24,34857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →